City
Epaper

Study finds Moderna's COVID-19 vaccine 90 pc effective six months after second dose

By ANI | Updated: April 14, 2021 20:20 IST

Moderna announced on Tuesday (local time) that their coronavirus vaccine was 90 per cent effective six months after a person receives their second dose.

Open in App

Moderna announced on Tuesday (local time) that their coronavirus vaccine was 90 per cent effective six months after a person receives their second dose.

The company in a statwement said that new results from a preclinical study of the Company's COVID-19 variant-specific vaccine candidates showed that the Company's variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. To date, the Company has delivered approximately 132 million doses of the Moderna COVID-19 Vaccine globally.

"Vaccine efficacy starting two weeks following the second dose and based on the updated adjudicated cases remains consistent with prior updates, including greater than 90% against all cases of COVID-19, and greater than 95% against severe cases of COVID-19," the company said in its statement.

According to The Hill, Moderna is working for its vaccine to be fully approved by the U.S. as it is only under emergency authorizations from the Food and Drug Administration.

"The Moderna team continues to make important progress with our COVID-19 Vaccine. We are looking forward to having the clinical data from our variant-specific booster candidates, as well as clinical data from the Phase 2/3 study of our COVID-19 Vaccine in adolescents," said Stephane Bancel, Chief Executive Officer of Moderna in a statement.

The CEO added: "The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants. Moderna will make as many updates to our COVID-19 vaccine as necessary until the pandemic is under control."

The study includes data from 900 coronavirus cases with over 100 of the cases being severe. Along with the updated efficacy of the vaccine, Moderna is currently working on its second phase for testing in adolescents, as reported by The Hill.

According to the news outlet, there are around 3,000 minors ages 12 to 17 fully enrolled in Moderna's trial and the company is working on enrolling children from 6 months to 11 years old.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Stéphane BancelCompanyFood And Drug AdministrationFood products, medicinesUnited states food and drug administrationCommissioner of food and drugs administrationUsfdaUnited states' food and drug administrationUnited states food & drug administrationU.s. food and drug administration
Open in App

Related Stories

HealthFDA Introduces ‘Chain of Risk’ Framework to Advance Tobacco Harm Reduction

MumbaiMumbai: FDA Destroys 218 Kg Fake Paneer and 478 Litres of Milk Ahead of Ganeshotsav

MumbaiMumbai: Man Caught Mixing Contaminated Water in Branded Milk Packets In Dahisar

MumbaiMumbai: FDA Suspends Caterers' License After MLA Sanjay Gaikwad Assaults Canteen Staff Over Food Quality

MumbaiMumbai: FDA Seizes Medicines Worth Rs 61.95 Lakh from Ghatkopar-Based Drug Firm

International Realted Stories

InternationalOver 2,000 Afghan refugees deported from Iran, Pakistan in single day

InternationalPak-based women's forum calls for return of forcibly disappeared Baloch people

InternationalSouth Korean PM encourages soldiers at front-line Army unit

InternationalFrom bonhomie to brinkmanship: India-US relations face test in Trump 2.0 era

InternationalISKP emerges as Pakistan’s new deniable proxy against India